SCHEMBL2843752

SCHEMBL2843752

N#Cc1ccccc1COc1ccc(C(C(=O)NO)c2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.57
MAOB P27338 2/20 0.51
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
HDAC5 Q9UQL6 1/20 0.50
ADAMTS4 O75173 1/20 0.50
MMP13 P45452 1/20 0.50
MMP1 P03956 3/20 0.46
ADAM17 P78536 2/20 0.46
KCNH2 Q12809 1/20 0.46
SPHK2 Q9NRA0 1/20 0.45
ALKBH1 Q13686 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2839114 0.81 FNTA (0.56) MAOBHDAC3HDAC4HDAC1HDAC7
SCHEMBL2844329 0.81 NR4A2 (0.59) MAOBHDAC3HDAC4HDAC1HDAC7
SCHEMBL2839201 0.80 MEN1 (0.60) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2841929 0.79 HDAC6 (0.62) FFAR1MAOBHDAC3HDAC4HDAC1
SCHEMBL2842960 0.76 HDAC1 (0.66) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9270379 0.76 FFAR1 (0.64) FFAR1MAOBADAMTS4MMP13KCNH2
SCHEMBL2847073 0.75 GSK3B (0.56) FFAR1MAOBHDAC3HDAC4HDAC1
SCHEMBL2846564 0.75 HDAC4 (0.64) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL20490486 0.75 HDAC4 (0.58) FFAR1HDAC3HDAC4HDAC1HDAC7
SCHEMBL2847556 0.75 HDAC3 (0.58) MAOBHDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139850-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2018-09-12 EP claimed
EP-2139850-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2010-01-06 EP claimed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US claimed
WO-2008122115-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-10-16 WO claimed
EP-2139850-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2018-09-12 EP disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
EP-2139850-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2010-01-06 EP disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
WO-2008122115-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 FFAR1 2662/4885MAOB 183/4885HDAC3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.